OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
POLTK$5065.0056

Politeknik Metal Sanayi ve Ticaret AS

Specialty ChemicalsVerified

The company's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage position. It maintains a strong liquidity position with a current ratio of 3.8, supported by cash and equivalents of 76.18 million TRY. The price-to-book ratio of 70.93 suggests the market is valuing the company's equity at a premium relative to its book value, which may reflect expectations of future growth or intangible assets not captured in the balance sheet. Profitability metrics show a mixed picture. The company reported a net loss of 22.75 million TRY, resulting in a negative return on equity of -8.5% and a return on assets of -6.19%. These figures are below the typical performance of the specialty chemicals industry, which generally expects positive returns on equity and assets. The gross profit margin of 30.9% is in line with industry norms, but the operating margin of 7.0% is weak, indicating inefficiencies in cost control or pricing power. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases exposure to sector-specific and regional economic risks. The absence of detailed segment reporting limits the ability to assess the performance of individual product lines or markets. Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a decline in revenue, with no clear indication of recovery in the next fiscal year. Historical revenue trends and the recent net loss suggest operational challenges, potentially linked to rising input costs or reduced demand in key markets. The capital expenditure of -5.99 million TRY indicates a reduction in investment, which may signal a strategic shift or financial constraints. Risk factors include the company's negative net income and weak operating margin, which could pressure liquidity if cash flow from operations does not improve. The low dilution risk is supported by no immediate filing-based flags, and the company has not issued additional shares recently. However, the high price-to-book ratio may be a red flag for investors if earnings do not recover, as it could lead to a revaluation downward. Recent events include the publication of the latest financial statements, which reveal the net loss and weak operating performance. No significant management changes or strategic announcements were disclosed in the available data. The company's filings do not indicate any material legal or regulatory issues, but the lack of positive momentum in earnings or cash flow could attract closer scrutiny from investors and analysts.

30-day price · POLTK-107.50 (-2.1%)
Low$4880.00High$6107.50Close$4957.50As of22 May, 00:00 UTC
Profile
CompanyPoliteknik Metal Sanayi ve Ticaret AS
TickerPOLTK.IS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Politeknik Metal Sanayi ve Ticaret AS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.

Classification. The company is classified under the Basic Materials economic sector, within the Chemicals business sector and the Specialty Chemicals industry, with a classification confidence of 0.92.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage position. It maintains a strong liquidity position with a current ratio of 3.8, supported by cash and equivalents of 76.18 million TRY. The price-to-book ratio of 70.93 suggests the market is valuing the company's equity at a premium relative to its book value, which may reflect expectations of future growth or intangible assets not captured in the balance sheet. Profitability metrics show a mixed picture. The company reported a net loss of 22.75 million TRY, resulting in a negative return on equity of -8.5% and a return on assets of -6.19%. These figures are below the typical performance of the specialty chemicals industry, which generally expects positive returns on equity and assets. The gross profit margin of 30.9% is in line with industry norms, but the operating margin of 7.0% is weak, indicating inefficiencies in cost control or pricing power. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases exposure to sector-specific and regional economic risks. The absence of detailed segment reporting limits the ability to assess the performance of individual product lines or markets. Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a decline in revenue, with no clear indication of recovery in the next fiscal year. Historical revenue trends and the recent net loss suggest operational challenges, potentially linked to rising input costs or reduced demand in key markets. The capital expenditure of -5.99 million TRY indicates a reduction in investment, which may signal a strategic shift or financial constraints. Risk factors include the company's negative net income and weak operating margin, which could pressure liquidity if cash flow from operations does not improve. The low dilution risk is supported by no immediate filing-based flags, and the company has not issued additional shares recently. However, the high price-to-book ratio may be a red flag for investors if earnings do not recover, as it could lead to a revaluation downward. Recent events include the publication of the latest financial statements, which reveal the net loss and weak operating performance. No significant management changes or strategic announcements were disclosed in the available data. The company's filings do not indicate any material legal or regulatory issues, but the lack of positive momentum in earnings or cash flow could attract closer scrutiny from investors and analysts.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 3.8 and significant cash reserves.
  • Despite a high gross profit margin, the company is unprofitable with a negative return on equity and assets.
  • The company's capital structure is conservative, with a low debt-to-equity ratio of 0.15.
  • The lack of segment and geographic diversification increases exposure to sector-specific and regional risks.
  • The company is not currently facing immediate liquidity or dilution risks, but its financial performance is a concern.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTRY
Revenue$609.0M
Gross profit$188.1M
Operating income$42.6M
Net income-$22.7M
R&D
SG&A
D&A
SBC
Operating cash flow$41.7M
CapEx-$6.0M
Free cash flow$3.3M
Total assets$367.7M
Total liabilities$99.9M
Total equity$267.8M
Cash & equivalents$76.2M
Long-term debt$40.9M
Valuation
Market price$5065.00
Market cap$18.99B
Enterprise value$18.96B
P/E
Reported non-GAAP P/E
EV/Revenue31.1
EV/Op income445.1
EV/OCF455.2
P/B70.9
P/Tangible book70.9
Tangible book$267.8M
Net cash$35.2M
Current ratio3.8
Debt/Equity0.1
ROA-6.2%
ROE-8.5%
Cash conversion-1.8%
CapEx/Revenue-1.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricPOLTKActivity
Op margin7.0%5.5% medp25 -0.0% · p75 10.8%above median
Net margin-3.7%4.1% medp25 0.1% · p75 8.8%bottom quartile
Gross margin30.9%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-1.0%-6.2% medp25 -13.4% · p75 -2.6%top quartile
Debt / equity15.0%37.1% medp25 10.3% · p75 82.0%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-23 01:13 UTC#0e4128e3
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 00:53 UTCJob: 99905225